Quantcast

Latest Management of cancer Stories

2014-10-14 23:11:32

There are nearly 400,000 teenagers and adults in America who are childhood cancer survivors, according to the “Cancer Facts and Figures 2014” from the American Cancer Society (ACS). Each is unique, their names and faces etched in the hearts of their medical caregivers; their stories providing encouragement to other children journeying through cancer treatment. St. Louis, MO (PRWEB) October 14, 2014 Many young survivors are finding continued hope and help through The National...

2014-10-14 08:33:18

SAN RAFAEL, Calif., Oct. 14, 2014 /PRNewswire/ -- Sanovas Inc., a Life Science company accelerating the development and commercialization of next-generation microinvasive diagnostics, devices and drug delivery technologies, announced today that US Patent No. 8,834,544 has issued to the Company. Photo - http://photos.prnewswire.com/prnh/20141013/151744 Logo - http://photos.prnewswire.com/prnh/20141013/151743LOGO The patent, entitled "Photodynamic Therapy for Tumors...

2014-10-08 23:14:36

Author meshes reality, fiction in new book to deliver story that highlights family reunion, breakthrough in technology CHULA VISTA, Calif. (PRWEB) October 08, 2014 The opportunity to examine the mysteries of his adoption and tell the success story about his cancer treatment inspired author Paul Raffer to craft a novel that cleverly meshes fiction and reality. In “Skin” (published by Xlibris) readers will follow the life and struggles of a doctor who was diagnosed with an incurable...

2014-10-07 23:00:40

Canada Cancer and Aging Research Laboratory (CCARL) launched in Lethbridge to provide personalized diagnostic and medical solutions for cancer treatment and to develop diagnostic criteria and therapeutic approaches to combat age-related diseases and aging itself. Lethbridge, AB, Canada (PRWEB) October 07, 2014 Canada Cancer and Aging Research Laboratory (CCARL) today announced the launch of its personalized medicine and research programs in Canada. The company plans to unfold its...

2014-10-07 12:31:24

LA JOLLA, Calif., Oct. 7, 2014 /PRNewswire/ -- Avidity NanoMedicines today announced that it has expanded its investor syndicate through the closing of a $6 million convertible note financing co-led by Fidelity Biosciences and TPG Biotech. Other investors in the financing include Brace Pharmaceuticals, Partner Fund Management, L.P. and existing investor Alethea Capital Management. Ben Auspitz from Fidelity Biosciences and Eran Nadav, Ph.D. from TPG Biotech will join Avidity's board as...

2014-10-07 08:28:48

University of Mannheim Medical Center is first site opened TORONTO and CHICAGO, Oct. 7, 2014 /PRNewswire/ - Pinnacle Biologics, Inc. ("Pinnacle"), a subsidiary of Concordia Healthcare Corp., ("Concordia") (TSX: CXR) (OTCQX: CHEHF), announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy. OPUS is an Open-label, multicenter phase 3 on the efficacy and safety of Photodynamic...

2014-10-02 12:28:31

LONDON, Oct. 2, 2014 /PRNewswire/ -- This report focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy. Cancer immunotherapy was once just a dream in the minds of physicians, clinicians and patients, but only recently (2010s era) has it actually been within reasonable reach. Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies covers three principle therapies that have been in the...

2014-10-02 08:24:49

LUGANO, Switzerland, October 2, 2014 /PRNewswire/ -- Rare cancer patients need access to innovative cancer drugs A consensus paper published in the Annals of Oncology today by Rare Cancers Europe (RCE) calls for new methodologies to be applied to clinical studies in rare cancers. RCE - a multi-stakeholder initiative representing patient associations, medical societies and industry - is calling both the community of researchers and European authorities to address...

2014-09-29 16:23:53

In the news release, The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 million by 2023, issued 18-Sep-2014 by Decision Resources Group over PR Newswire, we are advised by the company that the headline should read $3.8 billion rather than $3.8 million as originally issued inadvertently. The complete, corrected release follows: The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 billion...

2014-09-29 12:30:45

BOGOTA, Colombia, Sept. 29, 2014 /PRNewswire/ -- Cancer Treatment Institute of Colombia has announced a promising new drug treatment: a carefully formulated, first-of-its-kind combination of salinomycin and 3-bromopyruvate (3-BrPA) that has already proven successful at treating multiple types of cancer. The team of medical researchers behind this novel treatment are optimistic that it could significantly improve outcomes for many patients who have exhausted current therapeutic...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related